MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2

M. P. Gillam*, D. Nimbalkar, L. Sun, K. Christov, D. Ray, P. Kaldis, Xianpeng Liu, Hiroaki Kiyokawa

*Corresponding author for this work

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (CDKs) largely in tissue-specific manners. We and others previously demonstrated that adult mice deficient for the Cyclin D partner CDK4 (Cdk4-/- mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. Intriguingly, those neuroendocrine tissues affected in Cdk4-/- mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1). Mice with heterozygous disruption of the tumor suppressor Men1 gene (Men1+/-) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with MEN1 mutations. To explore the genetic interactions between loss of Men1 and activation of CDKs, we examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1+/- mice. A majority of Men1+/- mice with wild-type CDKs developed pituitary and islet tumors by 15 months of age. Strikingly, Men1+/-; Cdk4-/- mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. In contrast, Men+/-; Cdk2-/- mice showed pituitary and islet tumorigenesis comparable to those in Men1+/- mice. Pituitaries of Men1+/-; Cdk4-/- mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas tumors in Men1+/- mice and Men1+/-; Cdk2-/- mice exhibited LOH. Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (RB) at specific sites including Ser780. CDK2 knockdown had minimum effects on RB phosphorylation and cell cycle progression. These data suggest that CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.

Original languageEnglish (US)
Pages (from-to)932-938
Number of pages7
JournalOncogene
Volume34
Issue number7
DOIs
StatePublished - Feb 12 2015

Fingerprint

Multiple Endocrine Neoplasia Type 1
Islets of Langerhans
Carcinogenesis
Cyclin-Dependent Kinases
Retinoblastoma Protein
Loss of Heterozygosity
Pituitary Neoplasms
Cell Cycle
Phosphorylation
Cyclin D
Neoplasms
Neuroendocrine Cells
Insulinoma
Tumor Suppressor Genes

Keywords

  • Cell cycle
  • Insulinoma
  • Knockout mice
  • Menin
  • Pituitary

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Gillam, M. P., Nimbalkar, D., Sun, L., Christov, K., Ray, D., Kaldis, P., ... Kiyokawa, H. (2015). MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2. Oncogene, 34(7), 932-938. https://doi.org/10.1038/onc.2014.3
Gillam, M. P. ; Nimbalkar, D. ; Sun, L. ; Christov, K. ; Ray, D. ; Kaldis, P. ; Liu, Xianpeng ; Kiyokawa, Hiroaki. / MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2. In: Oncogene. 2015 ; Vol. 34, No. 7. pp. 932-938.
@article{44a9e74e85b740aea0f5e6f01ffc5689,
title = "MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2",
abstract = "Recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (CDKs) largely in tissue-specific manners. We and others previously demonstrated that adult mice deficient for the Cyclin D partner CDK4 (Cdk4-/- mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. Intriguingly, those neuroendocrine tissues affected in Cdk4-/- mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1). Mice with heterozygous disruption of the tumor suppressor Men1 gene (Men1+/-) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with MEN1 mutations. To explore the genetic interactions between loss of Men1 and activation of CDKs, we examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1+/- mice. A majority of Men1+/- mice with wild-type CDKs developed pituitary and islet tumors by 15 months of age. Strikingly, Men1+/-; Cdk4-/- mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. In contrast, Men+/-; Cdk2-/- mice showed pituitary and islet tumorigenesis comparable to those in Men1+/- mice. Pituitaries of Men1+/-; Cdk4-/- mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas tumors in Men1+/- mice and Men1+/-; Cdk2-/- mice exhibited LOH. Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (RB) at specific sites including Ser780. CDK2 knockdown had minimum effects on RB phosphorylation and cell cycle progression. These data suggest that CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.",
keywords = "Cell cycle, Insulinoma, Knockout mice, Menin, Pituitary",
author = "Gillam, {M. P.} and D. Nimbalkar and L. Sun and K. Christov and D. Ray and P. Kaldis and Xianpeng Liu and Hiroaki Kiyokawa",
year = "2015",
month = "2",
day = "12",
doi = "10.1038/onc.2014.3",
language = "English (US)",
volume = "34",
pages = "932--938",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "7",

}

Gillam, MP, Nimbalkar, D, Sun, L, Christov, K, Ray, D, Kaldis, P, Liu, X & Kiyokawa, H 2015, 'MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2', Oncogene, vol. 34, no. 7, pp. 932-938. https://doi.org/10.1038/onc.2014.3

MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2. / Gillam, M. P.; Nimbalkar, D.; Sun, L.; Christov, K.; Ray, D.; Kaldis, P.; Liu, Xianpeng; Kiyokawa, Hiroaki.

In: Oncogene, Vol. 34, No. 7, 12.02.2015, p. 932-938.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2

AU - Gillam, M. P.

AU - Nimbalkar, D.

AU - Sun, L.

AU - Christov, K.

AU - Ray, D.

AU - Kaldis, P.

AU - Liu, Xianpeng

AU - Kiyokawa, Hiroaki

PY - 2015/2/12

Y1 - 2015/2/12

N2 - Recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (CDKs) largely in tissue-specific manners. We and others previously demonstrated that adult mice deficient for the Cyclin D partner CDK4 (Cdk4-/- mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. Intriguingly, those neuroendocrine tissues affected in Cdk4-/- mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1). Mice with heterozygous disruption of the tumor suppressor Men1 gene (Men1+/-) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with MEN1 mutations. To explore the genetic interactions between loss of Men1 and activation of CDKs, we examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1+/- mice. A majority of Men1+/- mice with wild-type CDKs developed pituitary and islet tumors by 15 months of age. Strikingly, Men1+/-; Cdk4-/- mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. In contrast, Men+/-; Cdk2-/- mice showed pituitary and islet tumorigenesis comparable to those in Men1+/- mice. Pituitaries of Men1+/-; Cdk4-/- mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas tumors in Men1+/- mice and Men1+/-; Cdk2-/- mice exhibited LOH. Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (RB) at specific sites including Ser780. CDK2 knockdown had minimum effects on RB phosphorylation and cell cycle progression. These data suggest that CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.

AB - Recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (CDKs) largely in tissue-specific manners. We and others previously demonstrated that adult mice deficient for the Cyclin D partner CDK4 (Cdk4-/- mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. Intriguingly, those neuroendocrine tissues affected in Cdk4-/- mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1). Mice with heterozygous disruption of the tumor suppressor Men1 gene (Men1+/-) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with MEN1 mutations. To explore the genetic interactions between loss of Men1 and activation of CDKs, we examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1+/- mice. A majority of Men1+/- mice with wild-type CDKs developed pituitary and islet tumors by 15 months of age. Strikingly, Men1+/-; Cdk4-/- mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. In contrast, Men+/-; Cdk2-/- mice showed pituitary and islet tumorigenesis comparable to those in Men1+/- mice. Pituitaries of Men1+/-; Cdk4-/- mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas tumors in Men1+/- mice and Men1+/-; Cdk2-/- mice exhibited LOH. Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (RB) at specific sites including Ser780. CDK2 knockdown had minimum effects on RB phosphorylation and cell cycle progression. These data suggest that CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.

KW - Cell cycle

KW - Insulinoma

KW - Knockout mice

KW - Menin

KW - Pituitary

UR - http://www.scopus.com/inward/record.url?scp=84938489166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938489166&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.3

DO - 10.1038/onc.2014.3

M3 - Article

VL - 34

SP - 932

EP - 938

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 7

ER -

Gillam MP, Nimbalkar D, Sun L, Christov K, Ray D, Kaldis P et al. MEN1 tumorigenesis in the pituitary and pancreatic islet requires CDK4 but not Cdk2. Oncogene. 2015 Feb 12;34(7):932-938. https://doi.org/10.1038/onc.2014.3